Showing results (111-120 of 146) with videos related to
Sort By:
Pageof 15
Clinical & Experimental Metastasis|October 4, 2003
Enhanced green fluorescent protein-transfection of murine colon carcinoma cells: key for early tumor detection and quantificationJörg W Sturm, Michael A Keese, Beate Petruch, et al.Cancer|September 13, 2007
Loss of programmed cell death 4 expression marks adenoma-carcinoma transition, correlates inversely with phosphorylated protein kinase B, and is an independent prognostic factor in resected colorectal cancerGiridhar Mudduluru, Fabian Medved, Rainer Grobholz, et al.Trials|August 31, 2012
DeloRes trial: study protocol for a randomized trial comparing two standardized surgical approaches in rectal prolapse - Delorme's procedure versus resection rectopexySimone Rothenhoefer, Florian Herrle, Alexander Herold, et al.Onkologie|September 15, 2010
Annexin and survivin in locally advanced rectal cancer: indicators of resistance to preoperative chemoradiotherapy?Karoline Horisberger, Philipp Erben, Philipp Ströbel, et al.Journal of Gastroenterology|March 18, 2016
Carcinoma of the colon and rectum with deregulation of insulin-like growth factor 2 signaling: clinical and molecular implicationsDjeda Belharazem, Julia Magdeburg, Ann-Kristin Berton, et al.Anti-Cancer Drugs|May 14, 2009
Topoisomerase I expression correlates to response to neoadjuvant irinotecan-based chemoradiation in rectal cancerKaroline Horisberger, Philipp Erben, Benjamin Muessle, et al.International Journal of Radiation Oncology, Biology, Physics|June 10, 2008
Oxaliplatin and capecitabine-based chemoradiotherapy for gastric cancer--an extended phase I MARGIT and AIO trialRalf-Dieter Hofheinz, Frederik Wenz, Nadine Lukan, et al.Gastroenterology Research and Practice|September 10, 2016
Prognostic Impact of mRNA Expression Levels of HER1-4 (ERBB1-4) in Patients with Locally Advanced Rectal CancerMelanie Kripp, Kirsten Merx, Ralph Markus Wirtz, et al.Annals of Surgery|March 28, 2013
Pathohistological subtype predicts survival in patients with intraductal papillary mucinous neoplasm (IPMN) of the pancreasMarius Distler, Stephan Kersting, Marco Niedergethmann, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 3, 2005
Phase I trial of capecitabine and weekly irinotecan in combination with radiotherapy for neoadjuvant therapy of rectal cancerRalf-Dieter Hofheinz, Bolko von Gerstenberg-Helldorf, Frederik Wenz, et al.Pageof 15